LAGE-1 is also a cancer–testis antigen that is ideal for tumor immunotherapy because it is up-regulated in many tumor types including melanomas (Vaughan et al. 2004; Bolli et al. 2005; Kudela et al. 2011), ovary (Piura and Piura 2009; McCormack et al. 2013), lung (Bolli et al. 2005; Gure et al. 2005; Grunwald et al. 2006; McCormack et al. 2013), head and neck (Cuffel et al. 2011), prostate (Fossa et al. 2004; Hudolin et al. 2006) and bladder cancers (Sharma et al. 2006; Dyrskj et al. 2012) and so on, and highly restricted in normal tissues. Here, CTAG2 is linked to neoplasm.